Merck: Long-Term Follow-Up Data Reinforce Continued Overall

38-month median follow-up data from the Phase III JAVELIN Bladder 100 trial demonstrated prolonged median OS of 23.8 months with BAVENCIO plus best supportive care (BSC) in the first-line maintenance

Related Keywords

Canada , United States , United Kingdom , London , City Of , American , Noelle Piscitelli , Thomas Powles , American Society Of Clinical Oncology , Head Of Development Unit Oncology , Merck Press , European Commission , Drug Administration , Pfizer , Queen Mary University Of London , Serono , Solid Tumor Research At Barts Cancer Institute , American Cancer Society , Barts Cancer Centre , United Kingdom Based , Clinical Oncology , Genitourinary Cancers Symposium , Genitourinary Oncology , Solid Tumor Research , Barts Cancer Institute , Queen Mary University , Victoria Zazulina , Development Unit Oncology , Urothelial Carcinoma , Product Characteristics , Merck Press Releases , Cancer Journal , Accessed February , Merck , Song , Term , Follow , Data , Reinforce , Ontinued , Verall , Survival , Benefit , Avencio , Avelumab , First , Line , Maintenance , Treatment , Patients , Dvanced , Urothelial , Arcinoma ,